title: Novel form of miR-29b suppresses bleomycin-induced pulmonary fibrosis.
abstract: MicroRNA 29b (miR-29b) replacement therapy is effective for suppressing fibrosis in a mouse model. However, to develop clinical applications for miRNA mimics, the side effects of nucleic acid drugs have to be addressed. In this study, we focused on miRNA mimics in order to develop therapies for idiopathic pulmonary fibrosis. We developed a single-stranded RNA, termed "miR-29b Psh-match," that has a unique structure to avoid problems associated with the therapeutic uses of miRNAs. A comparison of miR-29b Psh-match and double-stranded one, termed "miR-29b mimic" indicated that the single-stranded form was significantly effective towards fibrosis according to both in vivo and in vitro experiments. This novel form of miR-29b may become the foundation for developing an effective therapeutic drug for pulmonary fibrosis.
authors.affiliation: Department of Molecular Pathology, Tokyo Medical University, Shinjuku, Tokyo, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Yamada
authors.affiliation: Department of Molecular Pathology, Tokyo Medical University, Shinjuku, Tokyo, Japan.
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Takanashi
authors.affiliation: Animal Research Center, Tokyo Medical University, Shinjuku, Tokyo, Japan.
authors.forename: Katsuko
authors.initials: K
authors.lastname: Sudo
authors.affiliation: Department of Molecular Pathology, Tokyo Medical University, Shinjuku, Tokyo, Japan.
authors.forename: Shinobu
authors.initials: S
authors.lastname: Ueda
authors.affiliation: Department of Molecular Pathology, Tokyo Medical University, Shinjuku, Tokyo, Japan.
authors.forename: Shin-Ichiro
authors.initials: SI
authors.lastname: Ohno
authors.affiliation: Department of Molecular Pathology, Tokyo Medical University, Shinjuku, Tokyo, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kuroda
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D001761:Bleomycin / Q000009:adverse effects*; D005347:Fibroblasts / Q000378:metabolism; D006909:Hydroxyproline / Q000032:analysis; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D035683:MicroRNAs / Q000627:therapeutic use*; D041681:NIH 3T3 Cells; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000188:drug therapy*; D015398:Signal Transduction; D051193:Toll-Like Receptors / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology
chemical_list: C547014:MIRN29 microRNA, mouse; D035683:MicroRNAs; D051193:Toll-Like Receptors; D016212:Transforming Growth Factor beta; D001761:Bleomycin; D006909:Hydroxyproline